- Home
- ELBM vs NXTC Comparison
ELBM vs NXTC Comparison
Compare ELBM & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELBM
- NXTC
- Stock Information
- Founded
- ELBM 2011
- NXTC 2015
- Country
- ELBM Canada
- NXTC United States
- Employees
- ELBM N/A
- NXTC N/A
- Industry
- ELBM Industrial Machinery/Components
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- ELBM Miscellaneous
- NXTC Health Care
- Exchange
- ELBM Nasdaq
- NXTC Nasdaq
- Market Cap
- ELBM 25.0M
- NXTC 23.0M
- IPO Year
- ELBM N/A
- NXTC 2019
- Fundamental
- Price
- ELBM $1.57
- NXTC $0.77
- Analyst Decision
- ELBM Strong Buy
- NXTC Strong Buy
- Analyst Count
- ELBM 1
- NXTC 2
- Target Price
- ELBM $5.20
- NXTC $4.00
- AVG Volume (30 Days)
- ELBM 40.6K
- NXTC 117.3K
- Earning Date
- ELBM 11-15-2024
- NXTC 03-20-2025
- Dividend Yield
- ELBM N/A
- NXTC N/A
- EPS Growth
- ELBM N/A
- NXTC N/A
- EPS
- ELBM N/A
- NXTC N/A
- Revenue
- ELBM N/A
- NXTC N/A
- Revenue This Year
- ELBM N/A
- NXTC N/A
- Revenue Next Year
- ELBM $1,630.56
- NXTC N/A
- P/E Ratio
- ELBM N/A
- NXTC N/A
- Revenue Growth
- ELBM N/A
- NXTC N/A
- 52 Week Low
- ELBM $1.04
- NXTC $0.76
- 52 Week High
- ELBM $3.00
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- ELBM 40.60
- NXTC 39.76
- Support Level
- ELBM $1.35
- NXTC $0.76
- Resistance Level
- ELBM $1.55
- NXTC $0.90
- Average True Range (ATR)
- ELBM 0.08
- NXTC 0.06
- MACD
- ELBM 0.00
- NXTC 0.01
- Stochastic Oscillator
- ELBM 32.35
- NXTC 19.58
About ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.